Abstracts tagged "Diagnostic Tests"

Abstract Number: 1859 • 2018 ACR/ARHP Annual Meeting
The Prognostic Value of Autoantibody Isotypes for Predicting Therapeutic Responses to Methotrexate in Patients with Rheumatoid Arthritis
Daniela Sieghart¹, Alexander Platzer², Farideh Alasti², Paul Studenic³, Maresa Grundhuber⁴, Sascha Swiniarski⁴, Stephan Blüml², Helmuth Haslacher⁵, Josef S. Smolen⁶ and Günter Steiner¹, ¹Division of Rheumatology, Department of Internal Medicine III, Medical University Vienna, Austria, Vienna, Austria, ²Division of Rheumatology, Department of Internal Medicine III, Medical University Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Thermo Fisher Scientific, Freiburg, Germany, Freiburg, Germany, ⁵Department of Laboratory Medicine, Medical University Vienna, Vienna, Austria, ⁶Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
Background/Purpose: Rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) are the most specific diagnostic markers of rheumatoid arthritis (RA). Lately we showed that the determination…
Abstract Number: 2184 • 2018 ACR/ARHP Annual Meeting
An Economic Evaluation on the Impact of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis Using Complement C4d Activation Products in a Multivariate Assay Panel (MAP)
Ann E. Clarke¹, Tom Goss², Andrew Piscitello³, Tarun Chandra³, Tyler O'Malley⁴, Thierry Dervieux⁴ and Tami Powell⁵, ¹Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ²Health Economics Outcomes Research, Boston Healthcare, Boston, MA, ³EmpiriQA LLC, Long Grove, IL, ⁴Exagen Diagnostics, Inc., Vista, CA, ⁵Corporate Payer Strategy & Reimbursement, Exagen Diagnostics, Inc., vista, CA
Background/Purpose: Diagnosis (dx) of systemic lupus erythematosus (SLE) is made via a combination of clinical and laboratory examinations; the sensitivity and specificity (S&S) of standard…
Abstract Number: 2402 • 2018 ACR/ARHP Annual Meeting
Acoustic Emissions Generated By the Temporomandibular Joint of Patients with Juvenile Idiopathic Arthritis and Their Implication on Patient Assessment and Screening: A Pilot Study
Daniel Whittingslow^1,2, Hyeon Ki Jeong³, Talia Gergely⁴, Lori Ponder⁴, Sampath Prahalad⁵, Omer Inan³ and Shelly Abramowicz⁶, ¹Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, ²Emory University School of Medicine, Atlanta, GA, ³Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA, ⁴Emory University, Atlanta, GA, ⁵Pediatrics, Emory University, Atlanta, GA, ⁶Surgery, Emory University/Children's Healthcare of Atlanta, Atlanta, GA
Background/Purpose: The temperomandibular joint (TMJ) is one of the most commonly affected joints in juvenile idiopathic arthritis (JIA) (up to 45% of cases). There is a discrepancy between…
Abstract Number: 2833 • 2018 ACR/ARHP Annual Meeting
Complement Activation Is a Feature of Diseases in the Lupus Spectrum
Rosalind Ramsey-Goldman¹, Roberta Alexander², Elena Massarotti³, Daniel J. Wallace⁴, Sonali Narain⁵, Cristina Arriens⁶, Christopher E. Collins⁷, Amit Saxena⁸, Chaim Putterman⁹, Kenneth C. Kalunian¹⁰, Armida Sace², Rowena Lafon², Tyler O'Malley², JoAnne Ligayon², Claudia Ibarra², John Conklin², Thierry Dervieux² and Arthur Weinstein⁷, ¹FSM, Northwestern University, Chicago, IL, ²Exagen Diagnostics, Inc., Vista, CA, ³Brigham and Women's Hospital, Boston, MA, ⁴Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Northwell Health, Great Neck, NY, ⁶Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Rheumatology, MedStar Washington Hospital Center/Georgetown University Medical Center, Washington, DC, ⁸NYU Langone Health, New York, NY, ⁹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY, ¹⁰Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA
Background/Purpose: We showed previously that complement activation - cell-bound complement activation products (CB-CAPS) or multi-analyte assay panel (MAP) - is a sensitive and specific biomarker…
Abstract Number: 172 • 2017 ACR/ARHP Annual Meeting
Optimizing Precision Medicine By Using Genetics to Assign Diagnostic Prior Probabilities to Patients with Synovitis
Rachel Knevel^1,2,3,4, Chikashi Terao^5,6,7, Jing Cui^1,8, Kamil Slowikowski^2,9,10, TWJ Huizinga³, Elizabeth Karlson¹¹ and Soumya Raychaudhuri^1,2,12,13, ¹Division of Medicine and Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Medical and Population Genetics Program, Broad Institute of MIT and Harvard, Cambridge, MA, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Bosten, MA, ⁵Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan, ⁶Clinical Research Center, Shizuoka General Hospital, Shizuoka, Japan, ⁷Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁸Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁹Division of Medicine and Rheumatology, Brigham and Women's Hospital, Harvard Medical Schoo, Boston, MA, ¹⁰Division of Genetics, Brigham and Women's Hospital, Harvard Medical Schoo, Boston, MA, ¹¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹²Department of Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom, ¹³Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: As the cost of genome-wide genotyping plummets, and biobanking efforts integrating medical records and genetics are rapidly expanding, many patients will have genotyping available…
Abstract Number: 441 • 2017 ACR/ARHP Annual Meeting
Social Media Based, Direct-to-Patient Study Designed for Development of “from Home” Testing for Rheumatoid Arthritis Patients Is Feasible and Engaged Individuals with Distinct Clinical Characteristics
Kristen Warren¹, Olga Derbeneva¹, Francisco Flores¹, Michelle Frits², James Healy¹, Christine Iannaccone³, Omar Khalid¹, Krishna Morampudi¹, Nancy Shadick⁴, Michael Weinblatt⁴, Hemani Wijesuriya¹ and Robert Terbrueggen¹, ¹DxTerity, Rancho Dominguez, CA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Physicians equipped with low cost, patient-administered, “from home” genomic tests for monitoring disease activity and therapy response could revolutionize treatment for rheumatoid arthritis…
Abstract Number: 581 • 2017 ACR/ARHP Annual Meeting
Diagnostic Value of Anti-CD74 Antibodies in Early Axial Spondyloarthritis: Data from the Spondyloarthritis Caught Early (SPACE) Cohort
Janneke de Winter¹, Marleen van de Sande¹, Niklas Thomas Baerlecken², Inger Berg³, Roberta Ramonda⁴, Désirée van der Heijde⁵, Floris van Gaalen⁶, Torsten Witte⁷ and Dominique Baeten^1,8, ¹Clinical Immunology and Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Rheumatology, Private Practice, Cologne, Germany, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy, ⁵Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷Clinical Immunology and Rheumatology, Medical University Hannover, Hanover, Germany, ⁸UCB Pharma, Slough, United Kingdom
Background/Purpose: Anti-CD74 IgG antibodies are reported to be elevated in serum of patients with axial spondyloarthritis (axSpA). This study aimed to assess the diagnostic value…
Abstract Number: 695 • 2017 ACR/ARHP Annual Meeting
Development of a Multimarker Model for the Detection of Systemic Lupus Erythematosus Based on New and Traditional Autoantibodies
Petra Budde¹, Hans-Dieter Zucht¹, Johannes Schulte-Pelkum¹, Daniel Wirtz¹, Torsten Witte², Matthias Schneider³ and Peter Schulz-Knappe¹, ¹Protagen AG, Dortmund, Germany, ²Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, ³Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany
Background/Purpose: Given the heterogeneity of clinical presentations, the diagnosis of Systemic Lupus Erythematosus (SLE) can be challenging, in particular in those patients presenting with early…
Abstract Number: 707 • 2017 ACR/ARHP Annual Meeting
Distinctive Features of Positive Anti-Cell Antibody Tests on HEp-2 Cells (HEp-2-ANA) in Patients with Non-Autoimmune Diseases
Renan Agustinelli¹, Sílvia H. Rodrigues², Mônica Prado³, Henrique Mariz⁴ and Luis Eduardo C. Andrade^5,6, ¹Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de Sao Paulo, São Paulo, Brazil, ²Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, Sao Paulo, Brazil, ³Rheumatology Division, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁴Internal Medicine Department, Hospital das Clínicas - Universidade Federal de Pernambuco, Recife, Brazil, ⁵Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil, ⁶Immunology Division, Fleury Medicine and Health, São Paulo, Brazil
Background/Purpose: The indirect immunofluorescence (IIF) test for anti-cell or antinuclear (ANA) antibodies on HEp-2 cells (HEp-2-ANA) is considered the gold standard method for ANA detection.…
Abstract Number: 1023 • 2017 ACR/ARHP Annual Meeting
The Autoimmune Discovery Ichip Distinguishes Healthy Individuals (HC) from Those with SLE, Rheumatoid Arthritis (RA), Scleroderma (SSc), Sjogren’s Syndrome (SS), and the Anti-Phospholipid Syndrome (APS)
Chaim Putterman¹, Armando Gabrielli², Alexandra Balbir-Gurman³, Pennina Safer⁴, Keren Jakobi-Brook⁴, Rachel Sorek⁴, Ilana Gluzman⁴, Steve Wallace⁵ and Irun R. Cohen^4,6, ¹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY, ²Istituto di Clinica Medica dell'Università di Ancona, Ancona, Italy, Ancona, Italy, ³Rheumatology Unit, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion, Haifa, Israel, Haifa, Israel, ⁴ImmunArray Ltd., Rehovot, Israel, Rehovot, Israel, ⁵ImmunArray Inc., VA, USA, Richmond, VA, ⁶Weizmann Institute of Science, Rehovot, Israel, Rehovot, Israel
Background/Purpose: Current serological tests are not sufficiently accurate in differentiating between HC and those with autoimmune rheumatic diseases. We developed the iCHIP antigen microarray to…
Abstract Number: 1096 • 2017 ACR/ARHP Annual Meeting
Clinical Significance of RNP Antibodies in Diagnosis of Systemic Autoimmune Rheumatic Disease When Detected By Multiplex Immunoassay
Heather Bukiri¹, Amish Dave², Erin Bauer², Vivian Stone², Chris Chong³ and Punam Verma⁴, ¹Graduate Medical Education, Virginia Mason Medical Center, Seattle, WA, ²Rheumatology, Virginia Mason Medical Center, Seattle, WA, ³Virginia Mason Medical Center, Seattle, WA, ⁴Microbiology/Immunology General Lab, Virginia Mason Medical Center, Seattle, WA
Background/Purpose: A large multicenter healthcare system recently adopted multiplex immunoassay as an initial screen for antinuclear antibody (ANA) with confirmatory reflex testing by immunofluorescence antibody…
Abstract Number: 1266 • 2017 ACR/ARHP Annual Meeting
Geographic Variation in Use of Echocardiography at Diagnosis and Detection of Acute Cardiac Disease in Youth with Systemic Lupus Erythematosus
Joyce C. Chang¹, Andrea M. Knight², Laura M. Mercer-Rosa³, Rui Xiao⁴ and Pamela F. Weiss⁵, ¹Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Division of Rheumatology, Center for Pediatric Clinical Effectiveness & PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, ³Division of Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Child-onset systemic lupus erythematosus (SLE) is a chronic autoimmune condition with a high risk of organ damage. There are no guidelines on the use…
Abstract Number: 1368 • 2017 ACR/ARHP Annual Meeting
Small RNA Sequencing Identifies Plasma microRNA Panel for Rheumatoid Arthritis Diagnosis
Michelle J. Ormseth¹, Joseph F. Solus², Quanhu Sheng², Yan Guo², Fei Ye², Ryan Allen², Kasey Vickers² and C Michael Stein², ¹Medicine, Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Small noncoding RNAs (sRNAs), such as microRNAs (miRNAs), are regulators of biological processes and serve as important biomarkers of disease. Most previous plasma sRNA…
Abstract Number: 1371 • 2017 ACR/ARHP Annual Meeting
Development of an Adjusted Multi-Biomarker Disease Activity (MBDA) Score for Rheumatoid Arthritis (RA) That Accounts for Age, Sex and Adiposity, with Subsequent Evaluation of Ability to Predict Risk for Radiographic Damage
Jeffrey R. Curtis¹, Darl D. Flake II², Michael Weinblatt³, Nancy A. Shadick⁴, Mikkel Østergaard⁵, Merete Lund Hetland⁶, Cecilie Heegaard Brahe⁶, Yong Gil Hwang⁷, Daniel E. Furst⁸, Vibeke Strand⁹, Carol J. Etzel¹⁰, Dimitrios A. Pappas¹¹, Xingbin Wang¹², Ching Chang Hwang¹³, Eric H. Sasso¹², Alexander Gutin², Elena Hitraya¹² and Jerry S. Lanchbury², ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Myriad Genetics Inc., Salt Lake City, UT, ³Brigham and Women’s Hospital, Boston, MA, ⁴Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, ⁶Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ⁷Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁸David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁹Stanford University, Palo Alto, CA, ¹⁰Departments of Epidemiology and Biostatistics, University of Texas School of Public Health, Houston, TX, ¹¹Columbia University, New York, NY, ¹²Crescendo Bioscience Inc., South San Francisco, CA, ¹³Biostatistics, Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose: The MBDA score, based on 12 serum proteins, is a validated tool for assessing disease activity in RA patients. MBDA biomarkers may be influenced…
Abstract Number: 1865 • 2017 ACR/ARHP Annual Meeting
Novel Approach to Arthritis Surveillance Suggests a Much Higher Prevalence of Arthritis Among US Adults Than Previous Estimate
S. Reza Jafarzadeh and David T. Felson, Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Current national estimates of arthritis prevalence in the United States rely on a single survey question about doctor-diagnosed arthritis from the National Health Interview…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.